MNKD
Price
$4.56
Change
-$0.07 (-1.51%)
Updated
May 9 closing price
Capitalization
1.39B
87 days until earnings call
PDSB
Price
$1.20
Change
-$0.02 (-1.64%)
Updated
May 9 closing price
Capitalization
54.81M
3 days until earnings call
Ad is loading...

MNKD vs PDSB

Header iconMNKD vs PDSB Comparison
Open Charts MNKD vs PDSBBanner chart's image
MannKind
Price$4.56
Change-$0.07 (-1.51%)
Volume$2.01M
Capitalization1.39B
PDS Biotechnology
Price$1.20
Change-$0.02 (-1.64%)
Volume$64.32K
Capitalization54.81M
MNKD vs PDSB Comparison Chart
Loading...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNKD vs. PDSB commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNKD is a StrongBuy and PDSB is a Buy.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (MNKD: $4.56 vs. PDSB: $1.20)
Brand notoriety: MNKD and PDSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNKD: 102% vs. PDSB: 14%
Market capitalization -- MNKD: $1.39B vs. PDSB: $54.81M
MNKD [@Biotechnology] is valued at $1.39B. PDSB’s [@Biotechnology] market capitalization is $54.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.13B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNKD’s FA Score shows that 0 FA rating(s) are green whilePDSB’s FA Score has 0 green FA rating(s).

  • MNKD’s FA Score: 0 green, 5 red.
  • PDSB’s FA Score: 0 green, 5 red.
According to our system of comparison, MNKD is a better buy in the long-term than PDSB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNKD’s TA Score shows that 4 TA indicator(s) are bullish while PDSB’s TA Score has 5 bullish TA indicator(s).

  • MNKD’s TA Score: 4 bullish, 5 bearish.
  • PDSB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, PDSB is a better buy in the short-term than MNKD.

Price Growth

MNKD (@Biotechnology) experienced а -8.80% price change this week, while PDSB (@Biotechnology) price change was -13.04% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Reported Earning Dates

MNKD is expected to report earnings on Aug 06, 2025.

PDSB is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.39B) has a higher market cap than PDSB($54.8M). PDSB YTD gains are higher at: -26.380 vs. MNKD (-29.082). MNKD has higher annual earnings (EBITDA): 77.5M vs. PDSB (-36.65M). MNKD has more cash in the bank: 197M vs. PDSB (49.8M). PDSB has less debt than MNKD: PDSB (24.7M) vs MNKD (47.7M). MNKD has higher revenues than PDSB: MNKD (286M) vs PDSB (0).
MNKDPDSBMNKD / PDSB
Capitalization1.39B54.8M2,529%
EBITDA77.5M-36.65M-211%
Gain YTD-29.082-26.380110%
P/E Ratio45.60N/A-
Revenue286M0-
Total Cash197M49.8M396%
Total Debt47.7M24.7M193%
FUNDAMENTALS RATINGS
MNKD vs PDSB: Fundamental Ratings
MNKD
PDSB
OUTLOOK RATING
1..100
1690
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
41
Fair valued
PROFIT vs RISK RATING
1..100
4196
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
6364
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PDSB's Valuation (41) in the Pharmaceuticals Major industry is in the same range as MNKD (60) in the Biotechnology industry. This means that PDSB’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Profit vs Risk Rating (41) in the Biotechnology industry is somewhat better than the same rating for PDSB (96) in the Pharmaceuticals Major industry. This means that MNKD’s stock grew somewhat faster than PDSB’s over the last 12 months.

PDSB's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as MNKD (100) in the Biotechnology industry. This means that PDSB’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Price Growth Rating (63) in the Biotechnology industry is in the same range as PDSB (64) in the Pharmaceuticals Major industry. This means that MNKD’s stock grew similarly to PDSB’s over the last 12 months.

MNKD's P/E Growth Rating (96) in the Biotechnology industry is in the same range as PDSB (100) in the Pharmaceuticals Major industry. This means that MNKD’s stock grew similarly to PDSB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNKDPDSB
RSI
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
68%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
86%
Advances
ODDS (%)
Bullish Trend 12 days ago
82%
Bullish Trend 12 days ago
86%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 5 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
88%
Aroon
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Ad is loading...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PDSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMWD58.62-0.14
-0.24%
American Woodmark Corp
TMHC58.67-0.48
-0.81%
Taylor Morrison Home Corp
MDLZ66.37-0.85
-1.26%
Mondelez International
KPTI6.01-0.14
-2.28%
Karyopharm Therapeutics Inc.
VERV4.23-0.25
-5.58%
Verve Therapeutics

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
-1.51%
VCYT - MNKD
44%
Loosely correlated
-4.81%
LXRX - MNKD
42%
Loosely correlated
+1.73%
INSM - MNKD
40%
Loosely correlated
-0.84%
BLUE - MNKD
38%
Loosely correlated
-5.66%
AMRN - MNKD
36%
Loosely correlated
-2.80%
More